Quantcast
Last updated on April 18, 2014 at 12:30 EDT

Latest Gynecologic oncology Stories

2010-05-17 06:30:00

QUEBEC CITY, May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate...

2010-05-06 06:30:00

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in...

868e989ecf796d04c1b96b7fb2eb74d21
2010-05-04 15:48:05

In the race to find answers about ovarian cancer, researchers now have something to cluck about. For five years, University of Illinois researchers have been using the chicken as a model to study this deadly disease and have recently discovered that a diet enriched with flaxseed decreases severity of ovarian cancer and increases survival in hens. Flaxseed is the richest plant source of alpha-linolenic acid, one type of omega-3 fatty acid. Several studies have already shown that flaxseed...

2010-05-03 10:59:00

CHICAGO, May 3 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) and The American College of Obstetricians and Gynecologists have named Marcia M. Humphrey Schmidt, MD, as the initial recipient of their jointly developed Breast Cancer Fellowship for gynecologic oncologists. After completing her fellowship in gynecologic oncology at the University of South Florida in June, Dr. Humphrey Schmidt will become the first to participate in the one-year fellowship training...

2010-04-21 09:47:00

Paper Provides Guidance to Clinicians Administering Advanced HPV Screening Technologies and its Future Research Needs CHICAGO, April 21 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published its second in a series of four papers on a variety of cervical cancer issues and topics that were the focus of its Forum "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare." The paper, entitled "What is the Role of HPV Typing in...

14ff9feea75291c7c12c7dbd41bd45a61
2010-04-07 10:21:28

On behalf of its founders, the Endometriosis Foundation of America (EFA) is extremely pleased to announce a landmark scientific symposium, "Advancing the Art & Science of Endometriosis: Stem Cells to Radical Excision Surgery", taking place on Thursday, May 20, 2010 in New York City. The event will be held at the prestigious New York Academy of Sciences and attended by elite speakers, panelists and attendees from around the globe. An expert consortium of faculty will present on topics...

2010-03-29 10:00:00

CHICAGO, March 29 /PRNewswire-USNewswire/ -- Daniel L. Clarke-Pearson, MD, Chairman of the Department of Obstetrics and Gynecology and Robert A. Ross Professor at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, has been elected the 42nd President of the Society of Gynecologic Oncologists (SGO) at the organization's 41st( )Annual Meeting, held March 14-17, 2010 in San Francisco, California. Dr. Clarke-Pearson received a Bachelor of Arts degree in...

2010-03-18 10:19:10

50 percent of patients respond to gemcitabine and cisplatin when used together Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients. Jubilee Brown, M.D., associate professor in M. D. Anderson's Department of Gynecologic Oncology, presented the findings at yesterday's plenary session of...

2010-03-17 05:00:00

ALISO VIEJO, Calif., March 17 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax(TM) assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent. The...

2010-03-16 10:00:00

SAN FRANCISCO, March 16 /PRNewswire/ -- The Gynecologic Cancer Foundation (GCF) and the Claudia Cohen Research Foundation announce today that Dr. Paul Goodfellow has been selected as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher. The prize is being presented at the Society of Gynecologic Oncologists (SGO) 41st Annual Meeting on Women's Cancer, meeting in San Francisco March 14-17, 2010. Dr. Goodfellow has made important...